Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Institut Pasteur de Lille, National University of Ireland Maynooth
InventorsCamille Locht, Bernard Mahon, Heather Kavanagh
Life of this patent
Estimating the term…
Abstract
The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
Claims4
A method for reducing airway inflammation in a subject which develops airway inflammation in response to exposure to an allergen, the method comprising the step of infecting the subject with a live Bordetella pertussis strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT), wherein the step of infecting the subject results in reduction of airway inflammation in said subject.
Dependencies are inferred from the claim text.